Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 plus Bevacizumab and HAIC for Potentially Resectable HCC
NCT07119931Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Sep 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab + tuvonralimab in hepatocellular carcinoma (HCC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Conversion Resection Rate at 12 months. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07119931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07119931.